Lipoprotein apheresis: a Hellenic consensus on its clinical use.

Competing Interests: Declaration of interest GK: participated in research and consulting activities sponsored by healthcare companies, including Amgen, MSD, Sanofi, and Servier; GG: VK: has participated in research studies sponsored by Amgen, Sanofi, and Regeneron; AM: participated in educational, research, and consulting activities sponsored by healthcare companies, including Lybitec, Lilly, Boehringer, Demo, Novo, Glaxo, Astra, and Amgen; HM: participated in educational, research and consulting activities sponsored by healthcare companies, including Amgen, Bayer, Mylan, MSD, Pfizer, Sanofi, and Servier; LR has received research grants, honoraria, and travel grants from Amgen, MSD, ELPEN, Sanofi, Mylan and Servier; DR: has participated in educational, research, and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer-Ingelheim, Elpen, Mylan, Unipharma, Lavipharm, and Servier; IS: has received research grants and honoraria from Amgen, Sanofi, MSD, and Elpen. LR has received honoraria for lectures, clinical trials, and consultant fees from Amgen, MSD, MYLAN, Servier, AstraZeneca, and Sanofi-Aventis; DT: participated in research and consulting activities sponsored by healthcare companies, including Amgen, MSD, Sanofi, Servier, Pfizer, and Boehringer-Ingelheim; CV has received research grant(s)/support and honoraria from Amgen, MSD, ELPEN, Sanofi, VIANEX; EL: has participated in educational, research, and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer-Ingelheim, Novartis, Novo Nordisk, and Servier; HB, SF, AG, EG, GK, SM: No conflict of interest to declare.